Monday, November 23, 2015
Pfizer has announced that PROFILE 1029, a phase III study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated East Asian patients with ALK-positive advanced non-small cell lung cancer (NSCLC) when compared to a standard chemotherapy doublet.
Thermo Fisher Scientific, based in Waltham, Mass., received a perfect score of 100 on the Human Rights Campaign’s annual 2016 Corporate Equality Index (CEI), making it a “Best Place to Work for LGBT Equality.” The CEI, a national benchmarking tool for lesbian, gay, bisexual and transgender workplace inclusion, provides an in-depth analysis and rating of large U.S. employers relevant to LGBT policies and practices.
The Pulse on Study Conduct by Elizabeth Weeks-Rowe
It is difficult to quantify a study coordinator’s responsibilities.
Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher Viehbacher, has launched Boston Pharmaceuticals, a fully integrated drug development company that will offer an innovative alternative model for drug development and commercialization.
Thermo Fisher Scientific has opened a new state-of-the-art GMP facility in Singapore. The company, which established its first clinical services facility there in 2001, said the move to the newly built facility will meet the growing demand for clinical supply services in the region. The new site will provide both regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies—from GMP storage, local labeling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to returns management.